ERS 2026 Highlights: COPD as a Modifiable Disease

The European Respiratory Society (ERS) Congress 2026, held in Barcelona, Spain, delivered a pivotal message regarding Chronic Obstructive Pulmonary Disease (COPD): it is a modifiable condition. Presentations highlighted advancements in patient outcomes through earlier diagnosis and innovative treatments, including the first successful Phase III trial of an anti-IL-33 biologic therapy.

Historically, many individuals with COPD receive late diagnoses, often exacerbating their condition despite treatment. The congress showcased two significant sessions, ALERT-1 and ALERT-2, which illustrated the potential for improvement in COPD management. The PREVAIL trial, presented in ALERT-1, demonstrated that a structured quality improvement program across 175 UK general practices led to a notable reduction in exacerbations, particularly among newly diagnosed patients. This trial emphasized the importance of optimizing existing care strategies.

Data from real-world studies further supported these findings. For instance, the COCARE study in Greece and a collaborative initiative in Northern Ireland reported improvements in guideline-based interventions and significant reductions in exacerbation rates. These studies underscored the need for proactive management and the integration of comprehensive care approaches, including cardiovascular risk assessments alongside COPD treatment.

Despite these advancements, challenges persist in the timely diagnosis of COPD. An analysis of over 55,000 patients in Australia revealed that individuals often undergo multiple consultations over several years before receiving a definitive diagnosis. A UK survey indicated that only a small percentage of healthcare professionals reported no delays in diagnosis, highlighting the need for systemic changes in diagnostic pathways. New approaches, such as the N-Tidal Diagnose capnography test, show promise for improving diagnostic accuracy and efficiency.

Looking ahead, the congress concluded with a strong call for continued collaboration among clinical, academic, and industry stakeholders to enhance COPD care. The integration of innovative diagnostic tools, proactive management strategies, and equitable access to treatment will be essential in transforming the landscape of COPD management. As enthusiasm for these advancements grows, it is crucial to ensure that the benefits reach those who need them most, paving the way for a brighter future in respiratory health.